Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.59 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | CLK3 | P49761 | 1/20 | 0.56 |
| ▸ | WNT1 | P04628 | 9/20 | 0.56 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29753907 | 1.00 | DYRK1A (0.59) | DYRK1ACLK2CLK3WNT1TLR8 | |
| SCHEMBL23534286 | 0.85 | DYRK1A (0.55) | DYRK1ACLK2CLK3WNT1GRM4 | |
| SCHEMBL29753964 | 0.85 | DYRK1A (0.53) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL23533888 | 0.85 | DYRK1A (0.53) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL29753971 | 0.85 | DYRK1A (0.55) | DYRK1ACLK2CLK3WNT1GRM4 | |
| SCHEMBL23534215 | 0.81 | DYRK1A (0.67) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL29754098 | 0.81 | DYRK1A (0.67) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL31123846 | 0.77 | DYRK1A (0.69) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL23533862 | 0.77 | DYRK1A (0.69) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL26394557 | 0.76 | DYRK1A (0.52) | DYRK1ACLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021125802-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | claimed |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) | 2023-04-13 | — | — | US | disclosed |
| EP-4079732-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021125802-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | DYRK1A 573/4885CLK2 342/4885CLK3 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.